Vice President, Program Leadership, Pioneering Medicines
Antonios (Tony) Aliprantis joined Flagship Pioneering in 2021 as Vice President of Program Leadership for Pioneering Medicines. He is responsible for leading cross functional teams to create integrated development strategies for therapeutic programs from lead optimization to human proof of concept, and he also contributes to new product concept explorations.
Previously, Tony was the Vaccines Therapeutic Area Lead in the Translational Pharmacology group at Merck where he oversaw a portfolio of early vaccine programs, including two mRNA vaccines and a monoclonal antibody to protect against a respiratory viral infection, and provided clinical pharmacology support for the successful filing of a small molecule therapy for heart failure. Prior to Merck, Tony was a faculty member at Brigham and Women’s Hospital and Harvard Medical School where he ran an NIH-funded laboratory investigating bone biology, inflammation, arthritis, and fibrosis and oversaw the Osteoarthritis Center which provided clinical care and conducted translational research.
Tony has co-authored over 45 publications and made contributions to articles published in Science, Proceedings of the National Academy of Sciences, and The Journal of Clinical Investigation. He received his M.D. and Ph.D. from NYU School of Medicine and his B.A. in Biochemistry from New York University.